Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/106039
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial
Author: Nicholls, S.
Lincoff, A.
Barter, P.
Brewer, H.
Fox, K.
Gibson, C.
Grainger, C.
Menon, V.
Montalescot, G.
Rader, D.
Tall, A.
McErlean, E.
Riesmeyer, J.
Vangerow, B.
Ruotolo, G.
Weerakkody, G.
Nissen, S.
Citation: American Heart Journal, 2015; 170(6):1061-1069
Publisher: Elsevier
Issue Date: 2015
ISSN: 0002-8703
1097-6744
Statement of
Responsibility: 
Stephen J. Nicholls, A. Michael Lincoff, Philip J. Barter, H. Bryan Brewer, Keith A.A. Fox, C. Michael Gibson, Christopher Grainger, Venugopal Menon, Gilles Montalescot, Daniel Rader, Alan R. Tall, Ellen McErlean, Jeffrey Riesmeyer, Burkhard Vangerow, Giacomo Ruotolo, Govinda J. Weerakkody, Steven E. Nissen
Abstract: Background: Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease. Study Design: ACCELERATE is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Patients qualified for enrollment if they have experienced an acute coronary syndrome within the prior 30 to 365 days, cerebrovascular accident, or transient ischemic attack; if they have peripheral vascular disease; or they have diabetes with coronary artery disease. A total of 12,092 patients were randomized to evacetrapib 130 mg or placebo daily in addition to standard medical therapy. The primary efficacy end point is time to first event of CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. Treatment will continue until 1,670 patients reached the primary end point; at least 700 patients reach the key secondary efficacy end point of CV death, myocardial infarction, and stroke, and the last patient randomized has been followed up for at least 1.5 years. Conclusions: ACCELERATE will establish whether the cholesteryl ester transfer protein inhibition by evacetrapib improves CV outcomes in patients with high-risk vascular disease.
Keywords: Cerebrovascular Disorders
Rights: Copyright © 2015 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.ahj.2015.09.007
Published version: http://dx.doi.org/10.1016/j.ahj.2015.09.007
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.